Quest Diagnostics Inc vs iShares Bitcoin Trust — how do they compare? Quest Diagnostics Inc trades at $237.08 (market cap $26.21B), while iShares Bitcoin Trust trades at $35.93. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while iShares Bitcoin Trust pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| DGX | IBIT | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | Crypto-linked |
52-Week High | $238.50 | $71.29 |
52-Week Low | $173.49 | $33.29 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
IBIT trades at $36.24, showing minimal daily movement with a 0.01% gain. Technical indicators signal a bearish trend with moving averages in sell territory, though oscillators remain neutral. The stock faces resistance at $37 and finds support at $36. Recent news highlights institutional interest in crypto ETFs, with BlackRock's digital assets head noting 'overwhelming demand' (Bloomberg, August 10, 2026).
The outlook remains cautious due to bearish technical signals and Bitcoin's 50% decline from 2025 peaks. Long-term potential exists via institutional adoption, but near-term risks include crypto market volatility and selective ETF inflows. Investors should weigh technical weakness against BlackRock's growing ETF footprint.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →